Why GLP-1 Doses Are Titrated: The Reasoning Behind the Ladder

Every GLP-1 schedule begins below the dose that produces the results, and moves up in timed steps. Patients often read this as caution for its own sake, or as a way to sell more months of treatment. It is neither. The interval is doing pharmacological work: gastrointestinal side effects are dose-related and cluster around dose changes, and a once-weekly drug takes several doses to approach steady state^[3]. Escalate faster and you are increasing the dose before the previous one has finished showing you what it does.

The two facts that produce the schedule

The first is that the adverse effects that limit these drugs are gastrointestinal — nausea, vomiting, diarrhea, constipation — and they are dose-related. A network meta-analysis comparing gastrointestinal adverse events across GLP-1 receptor agonists confirms this is a class-level pattern rather than a quirk of one molecule^[2]. The second is kinetic. Semaglutide's elimination half-life is approximately one week^[3], and tirzepatide's population pharmacokinetics likewise support weekly dosing^[4]. With a weekly interval and a weekly half-life, blood levels keep climbing for several doses after any increase before they plateau.

What the pivotal trial actually did

In the pivotal obesity trial of tirzepatide, every participant started at 2.5 mg once weekly — irrespective of the target dose they had been randomized to — and increased in 2.5 mg steps at four-week intervals until reaching their assigned dose^[1]. The design detail worth noticing is that the low starting dose was not a treatment arm. Nobody was assigned to stay there. It existed purely to get participants to a therapeutic dose with fewer dropouts along the way.

The two ways people get this wrong

Rushing. The temptation is understandable — the starting dose does little, and the results are at the top of the ladder. But compressing the interval front-loads the side effects that cause people to quit, and the drug that gets discontinued at week six delivers nothing at all. The schedule is not standing between you and the results; it is the route to staying on the medication long enough to get them.

Stalling. The mirror error is treating the starting dose as the destination. It was not evaluated as a treatment in the pivotal trial — every participant passed through it on the way to somewhere else^[1]. Someone who remains at the initiation dose indefinitely has completed the adaptation period without arriving at a dose the efficacy data describe. That may still be a reasonable clinical decision for an individual, but it should be a decision, not a default.

When holding a dose is the right call

• Side effects have not settled. If nausea from the last increase has not eased, stepping up adds a new increment on top of an unresolved one. Holding gives the current level time to become tolerable.
• You are losing weight steadily at the current dose. The target dose is where the trial measured efficacy, not a requirement for every individual. If the current dose is working, escalation is a discussion rather than an obligation.
• Intake has dropped too far. Very low food and fluid intake is a reason to pause and reassess rather than push through, particularly where dehydration is a risk.
• Something else changed. A new medication, an illness, or a procedure can alter tolerance, and the sensible response is usually to stay put until the picture is clear.

All four are decisions for the prescriber. The point of setting them out is that "hold at this dose" is a normal, anticipated part of the schedule rather than a failure of it — the trials themselves permitted dose adjustment for tolerability.